

## press release

### **Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access**

- New, lower list price of \$675 per month across Wegovy®, Ozempic®, and Rybelsus®, effective January 1, 2027, addresses access barriers to our innovative medicines, especially for patients whose out-of-pocket costs are linked to list price
- This action builds on concerted efforts from Novo Nordisk to improve patient access to Wegovy® and Ozempic® including savings offers, self-pay through NovoCare® Pharmacy, select telehealth relationships, and more
- These changes in list price do not have an impact on direct-to-patient, self-pay prices
- Wegovy®, Ozempic®, and Rybelsus® deliver powerful efficacy in addition to offering a broad range of indications unlike other GLP-1s

**Plainsboro, NJ, US and Bagsværd, Denmark, February 24, 2026** –Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic® (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, and Rybelsus® (semaglutide) tablets 7 mg or 14 mg to \$675, representing reductions of approximately 50% and 35% for Wegovy® and Ozempic®, respectively, from the current list price. This decision applies to all doses of these medicines and reflects Novo Nordisk’s commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system.

“Lowering the list price of Wegovy® and Ozempic® is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States. Private and public payers, as well as patients, want access and have been calling for lower list prices,” said Jamey Millar, executive vice president, US Operations of Novo Nordisk. “Our actions today answer that call and remove cost barriers so the value of Wegovy® and Ozempic® can be realized by more patients. The

lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs.”

Not all GLP-1s are the same. Semaglutide is the active ingredient in Wegovy® and Ozempic®, offering powerful efficacy and, unlike any other molecule in the GLP-1 class, it has FDA-approved medicines with indications for adults with obesity (Wegovy®), type 2 diabetes (Ozempic®), type 2 diabetes and chronic kidney disease (Ozempic® injection), and comorbid cardiovascular disease (Wegovy® and Ozempic®).

Through this action to lower list prices, Novo Nordisk seeks to improve access to these medicines for even more patients and is the latest in a series of efforts from Novo Nordisk, making it easier and more affordable for people in the US to get authentic, FDA-approved Wegovy® and Ozempic® in the way that best fits their lives. This change does not impact other access efforts, including direct-to-patient, self-pay prices.

### **About Wegovy®**

Wegovy® (semaglutide) injection 1.7 mg, 2.4 mg and 7.2 mg (currently approved only in the EU) and Wegovy® (semaglutide) tablets 25 mg (currently available in the US only) are prescription medicines used with a reduced-calorie diet and increased physical activity to reduce the risk of major cardiovascular events such as death, heart attack or stroke in adults with known heart disease and with either obesity or overweight. Moreover, Wegovy® helps adults with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems, to lose weight and keep the weight off.

*Novo Nordisk is a leading global healthcare company with a heritage of more than 100 years in diabetes care. Building on this foundation, our purpose is to drive change to defeat serious chronic diseases — from diabetes and obesity to rare blood and endocrine disorders — by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease. We are committed to long-term, responsible business practices that deliver financial, social and environmental value. Headquartered in Denmark and operating in around 80 countries, Novo Nordisk employs approximately 68,800 people and markets products in roughly 170 countries. In the United States, Novo Nordisk has a 40-year presence, is headquartered in New Jersey and employs approximately 10,000 people across more than 10 manufacturing, R&D, and corporate locations in eight states plus Washington, D.C. For more information, visit [novonordisk.com](http://novonordisk.com) and [novonordiskus.com](http://novonordiskus.com), and follow us on Facebook, Instagram, X, LinkedIn and YouTube.*

## Contacts for further information

### Media:

**Liz Skrbkova (US)**

+1 609 917 0632

[USMediaRelations@novonordisk.com](mailto:USMediaRelations@novonordisk.com)

**Ambre James-Brown (Global)**

+45 3079 9289

[Globalmedia@novonordisk.com](mailto:Globalmedia@novonordisk.com)

### Investors:

**Frederik Taylor Pitter (US)**

+1 609 613 0568

[fpitr@novonordisk.com](mailto:fpitr@novonordisk.com)

**Michael Novod**

+45 3075 6050

[nvno@novonordisk.com](mailto:nvno@novonordisk.com)

**Jacob Martin Wiborg Rode**

+45 3075 5956

[jrde@novonordisk.com](mailto:jrde@novonordisk.com)

**Sina Meyer**

+45 3079 6656

[azey@novonordisk.com](mailto:azey@novonordisk.com)

**Christoffer Sho Togo Tullin**

+45 3079 1471

[cftu@novonordisk.com](mailto:cftu@novonordisk.com)

**Max Ung**

+45 3077 6414

[mxun@novonordisk.com](mailto:mxun@novonordisk.com)

© 2026 Novo Nordisk All rights reserved. US26SEMO00479 February 2026